GlassScriptPhysician profile
Shamina Dhillon
NPI 1992779300
$2,584.72
in general payments reported to CMS, 2019-2025
23 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $53.74 · 2021: $14.97 · 2022: $288 · 2023: $273 · 2024: $872 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Education: $26.55 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.50 |
| Education | $26.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.26 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Pfizer INC. | $540.28 | 2019-2025 | |
| Sk Life Science, INC. | $249.16 | 2022-2024 | Xcopri |
| Takeda Pharmaceuticals U.S.A., INC. | $234.20 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.88 | 2024-2025 | Xifaxan |
| Janssen Biotech, INC. | $122.41 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $117.18 | 2024 | Krystexxa |
| Genzyme Corporation | $82.16 | 2024-2025 | |
| Madrigal Pharmaceuticals | $50.65 | 2025 | Rezdiffra |
| Celgene Corporation | $30.39 | 2023 | Zeposia |
| Daiichi Sankyo INC. | $28.70 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $28.31 | 2019 | |
| Intercept Pharmaceuticals, INC. | $27.16 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $26.82 | 2022 | |
| Gilead Sciences, INC. | $26.33 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $20.77 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.21 | 2024 | Iqirvo |
| Aimmune Therapeutics, INC. | $17.65 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.84 | 2024 | Dupixent |
| Mannkind Corporation | $16.02 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.46 | 2023 | Terlivaz |
| Lilly USA, LLC | $14.49 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $9.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamina Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.